Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu
A phase 3 trial of Zoldonrasib, Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Overview
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC is a phase 3 interventional study registered as NCT07777822 by Revolution Medicines, Inc., with 430 participants planned, started 2026-08-14 and due to reach its primary completion in 2029-10. Interventions recorded: zoldonrasib, Placebo, pembrolizumab, pemetrexed + cisplatin /carboplatin. Conditions listed: NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Shares Revolution Medicines, Pemetrexed, Cisplatin, Carboplatin.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Shares Zoldonrasib, Revolution Medicines, Cisplatin, Carboplatin.
- TrialDatopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.